Heart failure & cardiomyopathies
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
Authors' conclusion
The relative benefits of dapagliflozin were consistent across the range of LVEF regardless of the timing of the most recent HF hospitalization with a greater absolute benefit in patients with recent hospitalization.
Study context
- Population
- Patients with heart failure (HF) in DAPA-HF and DELIVER, by timing of prior HF hospitalizationpooled DAPA-HF and DELIVER
- Participants
- 11,007 patients
- Comparison
- Dapagliflozin vs placebo by timing of prior HF hospitalization
- Primary endpoint
- Worsening HF or CV death
Methodological detailspatient-level pooled analysis, placebo-controlled
- Patient-level pooled analysis
- Placebo-controlled
Primary result
As reported in the abstract
Worsening HF or CV death, by timing of prior HF hospitalization
Dapagliflozin vs PlaceboHazard ratio (95% CI)
0-3 months; NNT 13
0.66(0.55–0.81)
3-12 months; NNT 20
0.73(0.59–0.90)
>1 year; NNT 23
0.91(0.74–1.12)
No prior hospitalization; NNT 28
0.83(0.73–0.94)
Further findings
Timing of prior HF hospitalization (distribution)
- Within 3 months
- 12.4%
- 3-12 months
- 14.2%
- >1 year
- 16.8%
- Not hospitalized
- 56.5%
Risk of primary endpoint by time from prior HF hospitalization
- Risk inversely associated with time from prior HF hospitalization; highest with recent hospitalization
Effect by LVEF
- Beneficial effect consistent across LVEF regardless of HF hospitalization category
Original publication
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Fail. Published 3 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →